tiprankstipranks
Edwards Lifesciences Corp. (IT:1EW)
NYSE:1EW
Italy Market
1EW
Edwards Lifesciences
RESEARCH TOOLSreports

Edwards Lifesciences (1EW) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1EW Analyst Ratings

Strong Buy
19Ratings
Strong Buy
16 Buy
3 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Edwards
Lifesciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1EW Stock 12 Month Forecast

Average Price Target

€89.36
▲(18.48% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is €89.36 with a high forecast of €95.54 and a low forecast of €73.83. The average price target represents a 18.48% change from the last price of €75.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"€62","79":"€79","96":"€96","70.5":"€70.5","87.5":"€87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95.5448318,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€95.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.35613246749999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€89.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":73.83009729999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€73.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,70.5,79,87.5,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.68,76.28498706153847,77.88997412307693,79.49496118461539,81.09994824615384,82.70493530769231,84.30992236923078,85.91490943076923,87.5198964923077,89.12488355384616,90.72987061538461,92.33485767692308,93.93984473846153,{"y":95.5448318,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.68,75.80893326673078,76.93786653346154,78.06679980019231,79.19573306692308,80.32466633365385,81.45359960038462,82.58253286711538,83.71146613384614,84.84039940057691,85.96933266730768,87.09826593403845,88.22719920076922,{"y":89.35613246749999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.68,74.61462286923077,74.54924573846154,74.48386860769232,74.41849147692308,74.35311434615384,74.28773721538461,74.22236008461539,74.15698295384615,74.09160582307692,74.02622869230768,73.96085156153846,73.89547443076923,{"y":73.83009729999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.89,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.74,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.36,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€95.54Average Price Target€89.36Lowest Price Target€73.83
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on IT:1EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
€73.83
Hold
-2.11%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on IT:1EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
€91.2
Buy
20.93%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on IT:1EW
Patrick Wood
UBS
UBS
€78.17→€95.54
Buy
26.68%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on IT:1EW
Adam Maeder
Piper Sandler
Piper Sandler
€86.86→€87.73
Buy
16.32%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Truist Financial Analyst forecast on IT:1EW
Richard Newitter
Truist Financial
Truist Financial
€82.52
Hold
9.41%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Oppenheimer Analyst forecast on IT:1EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Leerink Partners Analyst forecast on IT:1EW
Mike Kratky
Leerink Partners
Leerink Partners
€75.57→€87.73
Buy
16.32%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Stifel Nicolaus Analyst forecast on IT:1EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€95.54
Buy
26.68%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
William Blair Analyst forecast on IT:1EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
07/24/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Atricure (ATRC)
BTIG Analyst forecast on IT:1EW
Marie Thibault
BTIG
BTIG
€95.54
Buy
26.68%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
TD Cowen Analyst forecast on IT:1EW
Josh Jennings
TD Cowen
TD Cowen
€90.33
Buy
19.77%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on IT:1EW
Shagun Singh Chadha
RBC Capital
RBC Capital
€95.54
Buy
26.68%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on IT:1EW
Travis Steed
Bank of America Securities
Bank of America Securities
€86.86
Buy
15.17%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Mizuho Securities Analyst forecast on IT:1EW
Anthony Petrone
Mizuho Securities
Mizuho Securities
€86.86→€91.2
Buy
20.93%
Upside
Reiterated
07/15/26
Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho
Citi Analyst forecast on IT:1EW
Joanne Wuensch
Citi
Citi
€87.73→€95.54
Buy
26.68%
Upside
Reiterated
07/08/26
Citi Keeps Their Buy Rating on Edwards Lifesciences (EW)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on IT:1EW
William Plovanic
Canaccord Genuity
Canaccord Genuity
€73.83
Hold
-2.11%
Downside
Reiterated
08/03/26
Balanced NTAP Tailwinds and Cautious TMTT Rollout Lead Plovanic to Maintain Hold Rating and Unchanged $85 Price Target on Edwards Lifesciences
J.P. Morgan Analyst forecast on IT:1EW
Robbie Marcus
J.P. Morgan
J.P. Morgan
€91.2
Buy
20.93%
Upside
Reiterated
07/28/26
J.P. Morgan Sticks to Their Buy Rating for Edwards Lifesciences (EW)
UBS Analyst forecast on IT:1EW
Patrick Wood
UBS
UBS
€78.17→€95.54
Buy
26.68%
Upside
Upgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Universal Health (NYSE: UHS), Insmed (NASDAQ: INSM) and Edwards Lifesciences (NYSE: EW)
Piper Sandler Analyst forecast on IT:1EW
Adam Maeder
Piper Sandler
Piper Sandler
€86.86→€87.73
Buy
16.32%
Upside
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Atricure (NASDAQ: ATRC) and Medpace Holdings (NASDAQ: MEDP)
Truist Financial Analyst forecast on IT:1EW
Richard Newitter
Truist Financial
Truist Financial
€82.52
Hold
9.41%
Upside
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Oppenheimer Analyst forecast on IT:1EW
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Edwards Lifesciences (NYSE: EW)
Leerink Partners Analyst forecast on IT:1EW
Mike Kratky
Leerink Partners
Leerink Partners
€75.57→€87.73
Buy
16.32%
Upside
Upgraded
07/24/26
Edwards Lifesciences upgraded to Outperform from Market Perform at LeerinkEdwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Stifel Nicolaus Analyst forecast on IT:1EW
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€95.54
Buy
26.68%
Upside
Reiterated
07/24/26
Stifel Nicolaus Keeps Their Buy Rating on Edwards Lifesciences (EW)
William Blair Analyst forecast on IT:1EW
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
07/24/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Atricure (ATRC)
BTIG Analyst forecast on IT:1EW
Marie Thibault
BTIG
BTIG
€95.54
Buy
26.68%
Upside
Reiterated
07/24/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
TD Cowen Analyst forecast on IT:1EW
Josh Jennings
TD Cowen
TD Cowen
€90.33
Buy
19.77%
Upside
Assigned
07/23/26
Edwards Lifesciences: Buy Rating Reaffirmed as Analyst Lifts Price Target from $85 to $104 on TAVR Momentum and TMTT Catalysts
RBC Capital Analyst forecast on IT:1EW
Shagun Singh Chadha
RBC Capital
RBC Capital
€95.54
Buy
26.68%
Upside
Reiterated
07/23/26
RBC Capital Keeps Their Buy Rating on Edwards Lifesciences (EW)
Bank of America Securities Analyst forecast on IT:1EW
Travis Steed
Bank of America Securities
Bank of America Securities
€86.86
Buy
15.17%
Upside
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Arcus Biosciences (RCUS)
Mizuho Securities Analyst forecast on IT:1EW
Anthony Petrone
Mizuho Securities
Mizuho Securities
€86.86→€91.2
Buy
20.93%
Upside
Reiterated
07/15/26
Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho
Citi Analyst forecast on IT:1EW
Joanne Wuensch
Citi
Citi
€87.73→€95.54
Buy
26.68%
Upside
Reiterated
07/08/26
Citi Keeps Their Buy Rating on Edwards Lifesciences (EW)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months
Adam MaederPiper Sandler
Success Rate
18/28 ratings generated profit
64%
Average Return
+1.52%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +1.52% per trade.
1 Year
Adam MaederPiper Sandler
Success Rate
23/28 ratings generated profit
82%
Average Return
+8.74%
Copying Adam Maeder's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +8.74% per trade.
2 Years
Larry BiegelsenWells Fargo
Success Rate
15/21 ratings generated profit
71%
Average Return
+10.32%
Copying Larry Biegelsen's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +10.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1EW Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
35
30
40
39
32
Hold
11
3
5
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
33
45
45
39
In the current month, 1EW has received 32 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 1EW average Analyst price target in the past 3 months is 89.36.
Each month's total comprises the sum of three months' worth of ratings.

1EW Financial Forecast

1EW Earnings Forecast

Next quarter’s earnings estimate for 1EW is €0.64 with a range of €0.63 to €0.67. The previous quarter’s EPS was €0.68. 1EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year 1EW has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1EW is €0.64 with a range of €0.63 to €0.67. The previous quarter’s EPS was €0.68. 1EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.82% of the time in the same period. In the last calendar year 1EW has Performed in-line its overall industry.

1EW Sales Forecast

Next quarter’s sales forecast for 1EW is €1.46B with a range of €1.43B to €1.48B. The previous quarter’s sales results were €1.51B. 1EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year 1EW has Performed in-line its overall industry.
Next quarter’s sales forecast for 1EW is €1.46B with a range of €1.43B to €1.48B. The previous quarter’s sales results were €1.51B. 1EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.46% of the time in the same period. In the last calendar year 1EW has Performed in-line its overall industry.

1EW Stock Forecast FAQ

What is IT:1EW’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences Corp.’s 12-month average price target is 89.36.
    What is IT:1EW’s upside potential, based on the analysts’ average price target?
    Edwards Lifesciences Corp. has 18.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Edwards Lifesciences Corp. a Buy, Sell or Hold?
          Edwards Lifesciences Corp. has a consensus rating of Strong Buy, which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Edwards Lifesciences Corp.’s share price target?
            The average share price target for Edwards Lifesciences Corp. is 89.36. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €95.54 ,and the lowest forecast is €73.83. The average share price target represents 18.48% Increase from the current price of €75.42.
              What do analysts say about Edwards Lifesciences Corp.?
              Edwards Lifesciences Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Edwards Lifesciences Corp.?
                To buy shares of IT:1EW, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.